| Hanover Counseling Associates, Pllc | |
|
7109 Studley Rd Mechanicsville VA 23116-6514 | |
| (804) 310-5351 | |
| Not Available |
| Full Name | Hanover Counseling Associates, Pllc |
|---|---|
| Speciality | Social Worker |
| Location | 7109 Studley Rd, Mechanicsville, Virginia |
| Authorized Official Name and Position | Lisa Corso Masouras (BUSINESS DIRECTOR/OWNER) |
| Authorized Official Contact | 8043105351 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Hanover Counseling Associates, Pllc 7109 Studley Rd Mechanicsville VA 23116-6514 Ph: (804) 310-5351 | Hanover Counseling Associates, Pllc 7109 Studley Rd Mechanicsville VA 23116-6514 Ph: (804) 310-5351 |
| NPI Number | 1114206778 |
|---|---|
| Provider Enumeration Date | 08/12/2011 |
| Last Update Date | 08/12/2011 |
| Medicare PECOS PAC ID | 3476701509 |
|---|---|
| Medicare Enrollment ID | O20120914000685 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
Neuroprosthetics - implants containing multi-contact electrodes that can substitute certain nerve functionalities - have the potential to work wonders.
Five years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus (MRSA) rates in Veterans Affairs (VA) medical centers, MRSA cases have continued to decline, according to a study in the November issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.
A world-first University of Melbourne-led study into the health and wellbeing of more than 154 million Indigenous and tribal people globally reveals the extent of work that needs to be done if the United Nations is to meet its 2030 goals of ending poverty and inequality.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114206778 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 0904006510 (Virginia) | Primary |
| Provider Name | Amy M Martin |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1831230663 PECOS PAC ID: 2567492135 Enrollment ID: I20050815000445 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
Neuroprosthetics - implants containing multi-contact electrodes that can substitute certain nerve functionalities - have the potential to work wonders.
Five years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus (MRSA) rates in Veterans Affairs (VA) medical centers, MRSA cases have continued to decline, according to a study in the November issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.
A world-first University of Melbourne-led study into the health and wellbeing of more than 154 million Indigenous and tribal people globally reveals the extent of work that needs to be done if the United Nations is to meet its 2030 goals of ending poverty and inequality.
› Verified 2 days ago
| Provider Name | Lisa C Masouras |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1467622803 PECOS PAC ID: 6800073313 Enrollment ID: I20110610000131 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
Neuroprosthetics - implants containing multi-contact electrodes that can substitute certain nerve functionalities - have the potential to work wonders.
Five years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus (MRSA) rates in Veterans Affairs (VA) medical centers, MRSA cases have continued to decline, according to a study in the November issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.
A world-first University of Melbourne-led study into the health and wellbeing of more than 154 million Indigenous and tribal people globally reveals the extent of work that needs to be done if the United Nations is to meet its 2030 goals of ending poverty and inequality.
› Verified 2 days ago
| Provider Name | Vivian Mann |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1740376318 PECOS PAC ID: 1254573777 Enrollment ID: I20130813000866 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
Neuroprosthetics - implants containing multi-contact electrodes that can substitute certain nerve functionalities - have the potential to work wonders.
Five years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus (MRSA) rates in Veterans Affairs (VA) medical centers, MRSA cases have continued to decline, according to a study in the November issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.
A world-first University of Melbourne-led study into the health and wellbeing of more than 154 million Indigenous and tribal people globally reveals the extent of work that needs to be done if the United Nations is to meet its 2030 goals of ending poverty and inequality.
› Verified 2 days ago
| Provider Name | Carrie S Meyer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1104361583 PECOS PAC ID: 8628326568 Enrollment ID: I20180808002938 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
Neuroprosthetics - implants containing multi-contact electrodes that can substitute certain nerve functionalities - have the potential to work wonders.
Five years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus (MRSA) rates in Veterans Affairs (VA) medical centers, MRSA cases have continued to decline, according to a study in the November issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.
A world-first University of Melbourne-led study into the health and wellbeing of more than 154 million Indigenous and tribal people globally reveals the extent of work that needs to be done if the United Nations is to meet its 2030 goals of ending poverty and inequality.
› Verified 2 days ago
| Provider Name | Kerrie Bogaz |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1568600377 PECOS PAC ID: 6800147265 Enrollment ID: I20180924002342 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
Neuroprosthetics - implants containing multi-contact electrodes that can substitute certain nerve functionalities - have the potential to work wonders.
Five years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus (MRSA) rates in Veterans Affairs (VA) medical centers, MRSA cases have continued to decline, according to a study in the November issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.
A world-first University of Melbourne-led study into the health and wellbeing of more than 154 million Indigenous and tribal people globally reveals the extent of work that needs to be done if the United Nations is to meet its 2030 goals of ending poverty and inequality.
› Verified 2 days ago
| Provider Name | Erika M Graves |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1326235367 PECOS PAC ID: 9436402617 Enrollment ID: I20181106000977 |
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
Neuroprosthetics - implants containing multi-contact electrodes that can substitute certain nerve functionalities - have the potential to work wonders.
Five years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus (MRSA) rates in Veterans Affairs (VA) medical centers, MRSA cases have continued to decline, according to a study in the November issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.
A world-first University of Melbourne-led study into the health and wellbeing of more than 154 million Indigenous and tribal people globally reveals the extent of work that needs to be done if the United Nations is to meet its 2030 goals of ending poverty and inequality.
› Verified 2 days ago
News Archive
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.
Neuroprosthetics - implants containing multi-contact electrodes that can substitute certain nerve functionalities - have the potential to work wonders.
Five years after implementing a national initiative to reduce methicillin-resistant Staphylococcus aureus (MRSA) rates in Veterans Affairs (VA) medical centers, MRSA cases have continued to decline, according to a study in the November issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
A new approach to combating the tubercle bacillus, the microorganism that kills some 1.5 million people in the world each year, has been developed by a French-British team including scientists from CNRS, Inserm, the Institut Curie and Université Toulouse III - Paul Sabatier.
A world-first University of Melbourne-led study into the health and wellbeing of more than 154 million Indigenous and tribal people globally reveals the extent of work that needs to be done if the United Nations is to meet its 2030 goals of ending poverty and inequality.
› Verified 2 days ago
Hope Counseling And Consultation Services, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 9291 Laurel Grove Rd, Suite 115, Mechanicsville, VA 23116 Phone: 804-317-5902 Fax: 804-509-0104 | |
Not Just Play, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6501 Mechanicsville Tpke Ste G3, Mechanicsville, VA 23111 Phone: 804-305-4621 Fax: 844-658-9554 | |
Nest Life Virginia, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5951 Dugout Ter, Mechanicsville, VA 23111 Phone: 727-201-2389 Fax: 855-224-4326 | |
Sensible Solutions Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 11025 Greenline Ct, Mechanicsville, VA 23116 Phone: 804-514-8114 | |
Care Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6620 Boundary Run Dr, Mechanicsville, VA 23111 Phone: 804-223-1366 | |
United Family Resources P C Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7516 Right Flank Rd, Suite 220, Mechanicsville, VA 23116 Phone: 804-559-4566 Fax: 804-559-1449 | |
Triple Willow Mental Health Clinic, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7300 Hanover Green Dr Ste 100, Mechanicsville, VA 23111 Phone: 804-781-4418 Fax: 804-212-0981 |